Navidea Biopharmaceuticals (NAVB) Announces Presentation Of Lymphoseek® Three-Year Recurrence And Survival Outcomes After Sentinel Lymph Node Biopsy In Patients With Breast Cancer And Melanoma
3/14/2014 8:44:15 AM
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results of a three-year, voluntary follow-up study of Lymphoseek® (technetium Tc 99m tilmanocept) Injection conducted in patients who participated in a Phase 3 clinical trial (NEO3-05) of the product. The primary objective of the follow-up study was to determine the regional (i.e., draining lymph node basin) recurrence-free rate (RRFR) after sentinel lymph node biopsy with Lymphoseek.
Help employers find you! Check out all the jobs and post your resume.
comments powered by